Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether ChromoGenics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as ChromoGenics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
ChromoGenics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
ChromoGenics's earnings available for a low price, and how does
this compare to other companies in the same industry?
ChromoGenics has negative assets, we can't compare the value of its assets to the SE Building industry average.
Take a look at our analysis of CHRO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through ChromoGenics's regulatory filings and announcements.
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ChromoGenics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Building industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare ChromoGenics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare ChromoGenics's earnings growth to the Sweden market average as no estimate data is available.
Unable to compare ChromoGenics's revenue growth to the Sweden market average as no estimate data is available.
Unable to determine if ChromoGenics is high growth as no earnings estimate data is available.
Unable to determine if ChromoGenics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
ChromoGenics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Jerker Lundgren was Founder and Chief Executive Officer of Skandinaviska Glassystem AB since 1994. Mr. Lundgren has 20+ years of experience within the construction and glass industry, including project management. Mr. Lundgren served as Managing Director of Hancap Façade and Chief Executive Officer of Hancap’s subsiduary Skandinaviska Glassystem AB. He has been a Director at ChromoGenics AB (publ) since June 2016 and served as its Director from June 2010 to June 2015. He holds M.Sc. in Civil engineering and Construction from Lund institute of Technology.
Insufficient data for Jerker to compare compensation growth.
Jerker's remuneration is lower than average for companies of similar size in Sweden.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the ChromoGenics management team is less than 2 years, this suggests a new team.
CEO & Director
Co-Founder & CTO
CFO & Head of Communications
Chief Operating Officer
Head of Sales
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the ChromoGenics board of directors is less than 3 years, this suggests a new board.
Board of Directors
Chairman of the Board
CEO & Director
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by ChromoGenics insiders in the past 3 months.
ChromoGenics AB (STO:CHRO): What Does Its Beta Value Mean For Your Portfolio?
If you're interested in ChromoGenics AB (STO:CHRO), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.
How Much Of ChromoGenics AB (STO:CHRO) Do Insiders Own?
I generally like to see some degree of insider ownership, even if only a little. … ChromoGenics is not a large company by global standards. … Our analysis of the ownership of the company, below, shows that.
How Much Are ChromoGenics AB (STO:CHRO) Insiders Spending On Buying Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. … It is perfectly legal for company insiders, including board members, to buy and sell stock in a company.
What Kind Of Investor Owns Most Of ChromoGenics AB (STO:CHRO)?
Generally speaking, as a company grows, institutions will increase their ownership. … Conversely, insiders often decrease their ownership over time. … institutional investors have bought into the company
In this article, I will take a quick look at ChromoGenics AB’s (STO:CHRO) recent ownership structure – an unconventional investing subject, but an important one. … A company's ownership structure is often linked to its share performance in both the long- and short-term. … Therefore, it is beneficial for us to examine CHRO's ownership structure in more detail.
Will You Be Burnt By ChromoGenics AB's (STO:CHRO) Cash Burn?
Additional cash raising may dilute the value of your shares, and since ChromoGenics is currently burning more cash than it is making, it’s likely the business will need funding for future growth. … How fast ChromoGenics runs down its cash supply over time is known as the cash burn rate. … ChromoGenics runs the risk of running down its cash supply too fast, or falling behind its profitable peers by investing too little.
Breaking Down ChromoGenics AB's (STO:CHRO) Ownership Structure
In this analysis, my focus will be on developing a perspective on ChromoGenics AB’s (OM:CHRO) latest ownership structure, a less discussed, but important factor. … Insider Ownership I find insiders are another important group of stakeholders, who are directly involved in making key decisions related to the use of capital. … Private Company Ownership Another important group of owners for potential investors in CHRO are private companies that hold a stake of 3.25% in CHRO.
Where ChromoGenics AB's (STO:CHRO) Earnings Growth Stands Against Its Industry
After reading ChromoGenics AB's (OM:CHRO) most recent earnings announcement (31 December 2017), I found it useful to look back at how the company has performed in the past and compare this against the latest numbers. … I prefer to use the ‘latest twelve-month’ data, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data. … OM:CHRO Income Statement Mar 21st 18 We can further assess ChromoGenics's loss by looking at what the industry has been experiencing over the past few years.
What Investors Should Know About ChromoGenics AB's (STO:CHRO) Financial Strength
Moving onto cash from operations, its operating cash flow is not yet significant enough to calculate a meaningful cash-to-debt ratio, indicating that operational efficiency is something we’d need to take a look at. … Maintaining a high level of debt, while revenues are still below costs, can be dangerous as liquidity tends to dry up in unexpected downturns.Next Steps: CHRO’s debt and cash flow levels indicate room for improvement. … Its cash flow coverage of less than a quarter of debt means that operating efficiency could be an issue.
ChromoGenics AB provides dynamic glass with controllable heat and light transmission in Sweden and internationally. The company offers ConverLight, an electrochromic glass, which provides UV protection for use in single glass pane and insulating glass unit solutions. It serves property owners, architects, building companies, and others in the glass industry. The company was founded in 2003 and is headquartered in Uppsala, Sweden.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.